The Shareholder’s Meeting of Esaote S.p.A. – a leading Company in the sector of diagnostic imaging – held in Genoa under the Chairmanship of Mr. Wu Guangming, has reconstituted its Board of Directors, expiring upon the approval of the company’s financial statements at 31.12.2018.
At the Shareholders’ Meeting of Esaote S.p.A. took notice of the resignation submitted by the CEO of the Group Karl-Heinz Lumpi and has appointed the new Board of Directors composed by Wu Guangming – confirmed Chairman – Franco Fontana, Eugenio Biglieri, Xie Yufeng, e Zheng Hongzhe.
The Board of Directors has immediately appointed Franco Fontana to the role of Chief Executive Officer.
Franco Fontana – who holds a doctorate in Computer Science and telecommunications at the University of Genoa and subsequently an Executive MBA at SDA Bocconi of Milan – has matured more than twenty years of experience in software applied to medical imaging and healthcare IT along a professional career that started as an entrepreneur and evolved as an executive manager. He took the direction of the Business Unit of EBIT AET, belonging to Esaote Group since 2008. Under his leadership, the Medical IT PACS business is constantly growing year after year, and Ebit has become a market leader in Italy and consolidated its international presence in Europe, Latin America and APAC.
To support Franco in his new role, effective immediately, Eugenio Biglieri has been appointed to the new role of Chief Operating Officer, with responsibilities spanning across Research & Development, Manufacturing, Operations, Strategic Marketing, Quality & Regulatory, and servicing of Medical Systems. Eugenio Biglieri joined Esaote in 1985, and over the years he has covered positions of increasing responsibility up to hold the roles of MRI Marketing Director and Chief Global service Officer.
The Board of Directors wishes to express its heartfelt gratitude to Karl-Heinz Lumpi for his commitment over the years to the leadership of Esaote. Mr Lumpi will continue to provide support over the coming months to complete the latest applications planned for the MyLab9 family.